- The European Commission approves Takeda's (OTCPK:TKPHF, TKPYY) $62B takeover of Shire (NASDAQ:SHPG), subject to the divestment of a Shire drug aimed at treating inflammatory bowel disease currently in development.
- The EC says Takeda agreed to the sale in order to ensure that the drug in Shire’s pipeline would continue to the market, where it is expected to compete with Entyvio, Takeda’s biggest-selling drug.
- Takeda already has secured unconditional clearance from regulators in the U.S., Japan, China and Brazil.
- Also: Advisory firms back Takeda's Shire buy (Nov. 20)
EU approves Takeda's takeover of Shire with divestment condition
Recommended For You
About TKPHF Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TKPHF | - | - |
Takeda Pharmaceutical Company Limited |